We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What Awaits Radius Health (RDUS) this Earnings Season?
Read MoreHide Full Article
Radius Health, Inc. (RDUS - Free Report) is scheduled to report second-quarter 2016 results on Aug 4. Last quarter, the company recorded a negative earnings surprise of 13.25%. Let’s see how things are shaping up for the company this quarter.
Factors Influencing This Quarter
Radius Health focuses on the development of therapeutics for the treatment of osteoporosis, oncology and endocrine diseases. Being a development-stage company with no approved products in its portfolio yet, it does not generate any revenue from product sales.
In this scenario, investors are expected to focus on pipeline updates by the company.
Radius Health’s efforts on developing its pipeline have been impressive. The company’s lead candidate, abaloparatide subcutaneous (abaloparatide-SC), is being developed for reducing the risk of fractures in postmenopausal osteoporosis. The candidate is currently under review in both the U.S. and the EU. It expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its application in late 2016 or in 2017.
We expect the company to shed further light on the regulatory front during its second-quarter conference call.
A potential approval would allow Radius Health to record its first commercial sales. The company is looking for a partner to commercialize abaloparatide. Meanwhile, the company continues to prepare for its U.S. launch, which includes hiring key experienced leaders for sales, marketing and managed care groups. Consequently, operating expenses are expected to increase as the company has been expanding its headcount in anticipation of a potential launch in the near future.
Moreover, Radius Health is developing abaloparatide-transdermal (abaloparatide-TD) patch for potential use as a treatment for osteoporosis. Other candidates in its pipeline include RAD1901 (in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women) and RAD140 (multiple indications including cancer). Research and development expenses are expected to increase due to pipeline development activities.
Earlier this year, the company collaborated with Novartis AG (NVS - Free Report) to evaluate the safety and efficacy of RAD1901 in combination with the latter’s LEE011.
The company expects its cash balance to be sufficient to fund development plans, commercial scale-up and other operational activities through 2018.
Surprise History
Radius Health has a disappointing track record so far. The company has missed estimates in all of the four trailing quarters with a negative average surprise of 15.62%.
Our proven model does not conclusively show that Radius Health is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) for this to happen. Unfortunately, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%, since both the Most Accurate estimate and the Zacks Consensus Estimate currently stand at a loss of 98 cents.
Zacks Rank: Radius Health carries a Zacks Rank #3. Although this increases the predictive power of ESP, the company’s 0.00% ESP makes surprise prediction difficult.
Conversely, we caution against stocks with Zacks Ranks #4 or #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Ironwood Pharmaceuticals (IRWD - Free Report) has an Earnings ESP of +13.33% and a Zacks Rank #2. The company is expected to report earnings on Aug 4.
Impax Laboratories has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is scheduled to report results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
What Awaits Radius Health (RDUS) this Earnings Season?
Radius Health, Inc. (RDUS - Free Report) is scheduled to report second-quarter 2016 results on Aug 4. Last quarter, the company recorded a negative earnings surprise of 13.25%. Let’s see how things are shaping up for the company this quarter.
Factors Influencing This Quarter
Radius Health focuses on the development of therapeutics for the treatment of osteoporosis, oncology and endocrine diseases. Being a development-stage company with no approved products in its portfolio yet, it does not generate any revenue from product sales.
In this scenario, investors are expected to focus on pipeline updates by the company.
Radius Health’s efforts on developing its pipeline have been impressive. The company’s lead candidate, abaloparatide subcutaneous (abaloparatide-SC), is being developed for reducing the risk of fractures in postmenopausal osteoporosis. The candidate is currently under review in both the U.S. and the EU. It expects an opinion from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for its application in late 2016 or in 2017.
We expect the company to shed further light on the regulatory front during its second-quarter conference call.
A potential approval would allow Radius Health to record its first commercial sales. The company is looking for a partner to commercialize abaloparatide. Meanwhile, the company continues to prepare for its U.S. launch, which includes hiring key experienced leaders for sales, marketing and managed care groups. Consequently, operating expenses are expected to increase as the company has been expanding its headcount in anticipation of a potential launch in the near future.
Moreover, Radius Health is developing abaloparatide-transdermal (abaloparatide-TD) patch for potential use as a treatment for osteoporosis. Other candidates in its pipeline include RAD1901 (in hormone-driven and/or hormone-resistant breast cancer, and vasomotor symptoms in postmenopausal women) and RAD140 (multiple indications including cancer). Research and development expenses are expected to increase due to pipeline development activities.
Earlier this year, the company collaborated with Novartis AG (NVS - Free Report) to evaluate the safety and efficacy of RAD1901 in combination with the latter’s LEE011.
The company expects its cash balance to be sufficient to fund development plans, commercial scale-up and other operational activities through 2018.
Surprise History
Radius Health has a disappointing track record so far. The company has missed estimates in all of the four trailing quarters with a negative average surprise of 15.62%.
RADIUS HEALTH Price and EPS Surprise
RADIUS HEALTH Price and EPS Surprise | RADIUS HEALTH Quote
What Our Model Indicates
Our proven model does not conclusively show that Radius Health is likely to beat estimates this quarter. That is because a stock needs to have both a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold) for this to happen. Unfortunately, that is not the case here, as you will see below.
Zacks ESP: The Earnings ESP, which represents the difference between the Most Accurate estimate and the Zacks Consensus Estimate, is 0.00%, since both the Most Accurate estimate and the Zacks Consensus Estimate currently stand at a loss of 98 cents.
Zacks Rank: Radius Health carries a Zacks Rank #3. Although this increases the predictive power of ESP, the company’s 0.00% ESP makes surprise prediction difficult.
Conversely, we caution against stocks with Zacks Ranks #4 or #5 (Sell-rated stocks) going into the earnings announcement, especially when the company is seeing negative estimate revisions.
Stocks That Warrant a Look
Here are a couple of health care stocks that you may want to consider, as our model shows that they have the right combination of elements to post an earnings beat this quarter.
Ironwood Pharmaceuticals (IRWD - Free Report) has an Earnings ESP of +13.33% and a Zacks Rank #2. The company is expected to report earnings on Aug 4.
Impax Laboratories has an Earnings ESP of +3.03% and a Zacks Rank #2. The company is scheduled to report results on Aug 9.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>